Investment Newsletters

Andrew Fein

Current Trading Levels Reflect Appropriate Value For VRTX Shares, Says H.C. Wainwright

In a research note released today, H.C.

Ben Mahaney, Editor — July 24, 2014, 1:01 PM EDT

H.C. Wainwright Reiterates Buy On Neptune; Sees 288% Upside For The Stock

H.C.

Ben Mahaney, Editor — July 18, 2014, 9:57 AM EDT

Epizyme Shares Will Perform Well In Next 6 Months, Says H.C. Wainwright’s Andrew Fein

H.C.

Editor Ben Weinberg — July 17, 2014, 1:20 PM EDT

H.C. Wainwright Initiates Buy On Epizyme; Sees 30% Upside For Stock

In a research note released this morning, H.C.

Editor Ben Weinberg — July 15, 2014, 1:51 PM EDT

H.C. Wainwright Downgrades Vertex Pharmaceuticals To Neutral, Lowers PT to $85

In a research report issued today, Vertex Pharmaceuticals (VRTX) was downgraded by analyst Andrew Fein at H.C.

Ben Mahaney, Editor — June 25, 2014, 9:14 AM EDT

H.C. Wainwright Reiterates Buy On Insmed Incorporated, $30 PT

In a research note released today, H.C.

Ben Mahaney, Editor — June 18, 2014, 4:14 PM EDT

H.C. Wainwright Reiterates Buy On United Therapeutics

In a research note issued this morning, H.C.

Ben Mahaney, Editor — June 16, 2014, 12:47 PM EDT

Vertex Shares Will Outperform The Biotech Sector, Says H.C. Wainwright

In a research note released this morning, H.C.

Ben Mahaney, Editor — June 16, 2014, 12:25 PM EDT

« 1 … 4 5 6